PROGRESS IN THE FIGHT
For Better Treatment, Prevention, a Vaccine, and a Cure for HIV, Tuberculosis, and Hepatitis C Virus
June 2021

Dear Friend of TAG:

This month marks the 40th anniversary of the U.S. government’s first reports of the emergence of what later became known as AIDS. Over those four decades, 76 million people became infected with HIV, and over 33 million have died from it. Thanks to research and activism, more than 26 million of the world’s 38 million people living with HIV are receiving lifesaving treatment. Though unacceptable gaps remain, the progress since — spurred in no small part by TAG’s informed, targeted, and tireless activism — has been remarkable.

Over 40 individual antiretroviral treatments (ART) have been approved. From no treatment at all, ART has evolved from complicated regimens with spotty efficacy and brutal side effects to simple pills or even monthly injections that durably reduce HIV to undetectable levels. Highly effective prevention options are available. Two individuals are known to have been cured. Thanks to TAG and our partners pushing for high standards, community engagement, and health justice, I watched the transformation of HIV infection from a frequently fatal condition among my friends to what is now a preventable and treatable condition — as long as prevention, therapy, care, and information are accessible.

As the HIV epidemic changes over time, and new pandemics continue to emerge, I’ve been amazed and proud at how TAG continues to evolve while remaining true to its activist roots. We partner with the most affected communities in the U.S. and around the world. After TAG accelerated the development of effective ART in the mid-1990s, we moved on to catalyze advocacy movements for the two deadliest coinfections of people with HIV — tuberculosis and hepatitis C. And in 2020, we began applying our unique science-based and community-driven voice, as well as the lessons learned over the past nearly three decades, to COVID-19.

It’s been such an honor to lead TAG’s Board of Directors over the past 25 years. I’m pleased to announce some changes to TAG’s Board of Directors. I am passing the Board President’s baton to Rob Lennon, who brings his brilliant leadership and dedication to TAG’s mission. The highly capable Mrinal Vikram is now our Secretary. Laura Morrison remains TAG’s steadfast Treasurer. I remain forever a part of TAG’s community, committed to advancing TAG’s vital work to end pandemics and the inequitable structures that allow them to flourish.

Your support has been central to TAG’s success over the past three decades, and particularly during this past year of overwhelming uncertainty. I know you’ll find inspiration in reading about the amazing work the TAG staff and partners accomplished in spite of all the challenges during 2020. I hope you will continue — as I will — to support TAG so we can accelerate the end of these pandemics once and for all.

Yours in the fight,

Barbara Hughes

President Emeritus, Board of Directors
We held our annual Research in Action Awards virtually for the first time on Thursday, November 19, 2020. Journalist and activist Ann Northrop was our host, and the multitalented Rachel York treated our audience to amazing performances. Dr. Jonathan LaPook of CBS News moderated a compelling roundtable discussion with panelists Dr. Wafaa El-Sadr, Dr. Trip Gulick, and Annette Gaudino. Our wonderful honorees were Dr. Anthony S. Fauci, National Nurses United, Wakefield, and Sharon Stone. Mark Harrington talked about TAG’s many achievements in this difficult year, and our event chair Bob Bronzo made a moving appeal. Cameos, many of them from previous RIAA honorees, lit up the screen: Amanda Lugg, Peter Staley, Lynda Dee, Greg Millett, Dr. Mary T. Basset, David France, Alan Cumming, Judith Light, Matthew Lopez, Jon Cohen, Kevin Goetz, and Barbara Hughes. You can relive the wonderful evening here.

Anthony S. Fauci, M.D.

“... And so, to my dear friends and colleagues with whom I have worked with at TAG, thank you very much for this award. It means a great deal to me. Together, we have accomplished much, and for this, we can feel proud and energized for the inevitable challenges ahead.”

Bonnie Castillo, National Nurses United

“All along the way we have spoken up for our Black, Brown, and Indigenous patients who have been hit hard by this pandemic, especially given the racial injustice that is inseparable from health care injustice in this country.”

Sharon Stone

“I’m here to scream for joy for all the work that you’re doing at TAG, and I’m here to say, I could not be more humbled, more honored, or more devoted to this journey in my life to end HIV/AIDS in my lifetime and to continue to work with the Treatment Action Group in whatever way they’ll have me.”

Wakefield

“This award from TAG touches me most deeply, however, because our association did not begin with the current pandemic; we go back decades. We have gone through the wars together.”
### HIV PROJECT

- TAG’s Basic Science, Vaccines, and Cure Project Director Richard Jefferys published an analysis of HIV cure-related clinical trials, highlighting important issues such as the continuing underrepresentation of women. Richard spoke to the *New York Times* about the second individual to be cured of HIV.

- TAG hired Edric Figueroa as the first ACT NOW: END AIDS (ANEA) Coalition Coordinator. With ANEA, we supported diverse community groups in Alabama, Dallas, Los Angeles, Memphis, and New Orleans to fund and carry out local work to end the HIV epidemics there.


- TAG published four TAG HIV pipeline reports, along with its first COVID-19 pipeline.

- TAG waged a successful campaign with partners to ensure the participation of people with HIV in the phase III COVID-19 vaccine trials sponsored by Moderna and Pfizer.

- With allies, TAG launched a call to end racism and over-policing in NYC, called on New York’s Board of Health to declare these a public health emergency, and deplored the politically motivated resignation of NYC Health Commissioner Dr. Oxiris Barbot.

- TAG’s “Landscape Analysis of HIV Cure-Related Clinical Research” was published in the *Journal of Virus Eradication*, and a companion community summary was made available on our website.

- ANEA launched a new website and revised the executive summary for the coalition’s community roadmap to end HIV in the U.S.

- TAG hired our first HIV Community Engagement Officer, Abraham Johnson, MPH, to strengthen community involvement with the HIV Vaccine Trials Network, Black AIDS Institute, and the COVID Prevention and Vaccine Trials Network (CoVPN).

- Edric, speaking for ANEA, participated in a panel at the Presidential Advisory Council on HIV/AIDS (PACHA) meeting on the future of the federal ending HIV Initiative. ANEA provided a robust transition memo to the Biden-Harris Administration detailing the need for a human rights approach and community leadership in the incoming administration’s HIV response.

- TAG, in partnership with the Black AIDS Institute and the HIV Vaccine Trials Network, launched the first We The People Research Cohort to train advocates from underrepresented U.S. communities to participate in HIV prevention research advocacy.

---

**“As a long-time activist, I cannot underestimate the importance of TAG’s work in our world.”**

– Amanda Lugg, RIAA 2020

**“Thank you, TAG, for leading the fight to end HIV, tuberculosis, and hepatitis C, and now COVID-19, for everyone around the world.”**

– Rachel York, RIAA 2020
Advocacy by TAG’s TB team, including members of Guideline Development Groups, resulted in strong recommendations for improved diagnostics and treatment regimens by the WHO. To help activists unpack these updated guidelines and hold governments accountable for ensuring access to higher diagnostic and treatment standards, the TB team launched *An Activist’s Guide to Tuberculosis Diagnostic Tools* and *An Activist’s Guide to Treatment for Drug-Resistant Tuberculosis*.

TAG secured a major win for human rights when a United Nations body issued a progressive General Comment on the right to science incorporating TAG’s input.

TAG and civil society partners in 10 countries advocated for access to the best TB preventive therapy. TAG and partners in India, Thailand, and France successfully resisted spurious attempts by Big Pharma to patent two decades-old medicines used to prevent TB (isoniazid and rifapentine) by publishing an *Access Roadmap and Patent Landscape* on the two drugs with statements supporting patent oppositions.

TAG, with the Médecins Sans Frontières (MSF) Access Campaign, expanded the scope and reach of the *Time for $5 Campaign*, a global civil society movement calling on Cepheid to reduce the prices of Xpert rapid tests for TB, HIV, HCV, COVID-19, and other conditions to $5.

TAG refreshed and diversified the membership of its Global Tuberculosis Community Advisory Board (TB CAB), adding members from India, Kenya, Moldova, Peru, Ukraine, and Zimbabwe, and convened annual meetings with key TB research and product sponsors virtually.

TAG published, in PLOS ONE, a comprehensive review of public, foundation, and corporate investment in developing bedaquiline, the first new TB drug in a new class approved in fifty years, showing that the public sector (mainly the U.S. government) invested between 160 percent and 500 percent more than the company in this breakthrough drug, now the cornerstone of drug-resistant TB treatment. This landmark article is among the most in-depth, comprehensive peer-reviewed articles showing the evidence for public versus private investments in developing any drug. Leveraging these findings, TAG and the TB CAB called for J&J, the manufacturer, to reduce the drug’s price to $1/day.

TAG’s TB and policy teams launched a policy brief showing how tools, concepts, capacity, and infrastructure established through years of public investments in TB R&D have informed COVID-19 research and responses.

New studies for which TAG advocated over the past decade showed that drug-sensitive TB can now be cured in four rather than six months in both adults and children. A TAG-led community advisory board played a leading role in disseminating these results.

The TB team published four pipeline report chapters, reviewing recent progress in the development of new TB diagnostics, treatments, preventive therapy, and vaccines. With the Stop TB Partnership, TAG published *Tuberculosis Research Funding Trends, 2005–2019*, the 15th in a series of influential reports tracking global funding for TB research.

The policy and TB teams coordinated advocacy for TB research and program investment by the U.S. Congress, promoting increased R+D investment and preserving TB program funding in Indiana and New York.

> Whenever there’s a new epidemic, like Ebola, and now COVID, AIDS activists step up to the plate. We’re the first to do it, TAG is the first to do it.  
> – Peter Staley, RIAA 2020
**POLICY 2020**

- TAG’s policy team achieved funding increases to many of the organization’s priority issues in fiscal year (FY) 2021 appropriations, in the midst of the COVID-19 pandemic, nationwide demonstrations calling for long-overdue racial justice, and a hotly disputed election cycle. Among agencies receiving increased federal funding for fiscal year 2021 were USAID’s Global Accelerator to End TB (+$9 million), NIH HIV research (+$14 million), CDC viral hepatitis research (+$500,000), and the CDC’s Ending the HIV Epidemic Initiative (+$35 million).

- TAG’s Senior Government Relations and Policy Officer Lizzy Lovinger spoke at the Presidential Advisory Council on HIV/AIDS (PACHA), expressing TAG’s strong support for increased HIV research funding due to COVID-19 disruptions, the need for rigorous ethical standards, and the dangers of political interference in research.

- With AVAC and HealthGAP, TAG condemned the unwise U.S. move to withdraw its membership and funding support for the WHO.

- Lizzy was elected co-chair of the Tuberculosis Roundtable coalition, where she will lead and facilitate federal and global TB advocacy initiatives. Lizzy participated in several meetings with the Biden-Harris transition team to discuss global health community requests.

- TAG’s policy team collaborated with TAG’s HIV, HCV, and TB projects to publish a landmark series of policy briefs on how investments in HIV, TB, and HCV research have profoundly benefited and accelerated science’s ability to respond to COVID-19.

- Due to the relentless advocacy of TAG’s Annette Gaudino over many years, in September 2020, New York State removed prior authorization requirements for HCV cures for NYS Medicaid, correctional, and privately insured individuals, allowing combination therapy cures for hepatitis C virus (HCV) and making it easier for these New Yorkers to be cured of HCV infection. Building on this win, five additional states are now removing these barriers to HCV cures.

**HCV PROJECT**

- TAG convinced the President’s Emergency Plan for AIDS Relief (PEPFAR) to expand its country guidance for viral hepatitis including HCV testing, treatment, and cure for people coinfected with HIV and HCV in PEPFAR focus countries.

- TAG HCV Project Director Bryn Gay collaborated on the first meeting between harm reductionists, community representatives, and new officials at the Georgian Ministry of Health, resulting in the establishment of a ministry-community steering committee to implement treatment guideline changes, community recommendations, and action plans to reduce or eliminate HCV infection in the Republic of Georgia. Plans for sustaining engagement have been paused due to COVID-19.

- Bryn and TAG Policy Strategy Director Annette Gaudino published an issue brief, in English and French, on difficult-to-treat hepatitis C subtypes found in sub-Saharan Africa and its diaspora.

- The HCV and TB teams joined the Unitaid-funded LONGEVITY project to support community engagement in clinical trials development of long-acting treatments for HCV, TB, and malaria. TAG held preliminary discussions with the Medicines Patent Pool and the LONGEVITY project’s commercial partner Tandem Nano Ltd to assess alternative incentives (other than exclusivity in rich countries) in the related voluntary licensing agreements, which would expand future generics access.

- Bryn catalyzed diagnostics advocacy and informed a community wishlist in Malaysia, leading to the adoption of numerous policy changes, such as free HCV testing and treatment, including in some harm reduction sites.

- Bryn spoke on HCV diagnostics literacy and community engagement work at a World Hepatitis Day webinar and made recommendations on new indicators at the first World Health Organization (WHO) Viral Hepatitis Elimination Validation meeting.
Bryn and Annette launched the 2020 HCV Pipeline Report, which won praise from the Director of the CDC Division of Viral Hepatitis.

Bryn, Mark Harrington, and Suraj Madoori met with the new WHO Head of HIV, Viral Hepatitis, and STI Division, Dr. Meg Doherty, about TAG’s HCV priorities, where they gained commitments to wider community consultations and succeeded in getting our recommended community representatives accepted for the WHO Key Populations Guidelines meeting.

Bryn provided a comprehensive and detailed orientation with our new HCV Community Engagement Officer Joelle Dountio Ofimboudem to support the LONGEVITY project’s community engagement activities, particularly around long-acting formulations for HCV.

With the TB Team, Bryn and Joelle managed consultants’ preparations of a patent landscape and access strategy report for long-acting glecaprevir/pibrentasvir (Mavyret for HCV), rifapentine, isoniazid, delamanid, and bedaquiline for TB. The report will be launched in 2021 and will inform community workshops.

COVID-19 RESPONSE

In March 2020, TAG rapidly and smoothly shifted its internal operations and advocacy work in response to the global COVID-19 pandemic while continuing to advance existing work in HIV, HCV, and TB research and advocacy. Jeremiah Johnson and Mark Harrington cofounded a virtual New York–focused COVID-19 Working Group, which several TAG staff participated in, in partnership with community partners and with support from Columbia University School of Social Work and generous gifts to TAG from long-time supporters.

Bryn Gay drafted global principles on access to COVID-19 medicines, technologies, and innovation, adapted them for the U.S. context and in a letter to the G20 health ministers, and promoted them while mentoring a “squad” of activists in the Salk Advocacy Innovation Lab, a network of over 300 activists in 29 countries demanding a free and accessible vaccine for all.

Columbia University professor Wafaa El-Sadr and Mark coordinated a letter by the COVID Working Group urging the city to establish safe spaces for vulnerable individuals with presumed or diagnosed mild/moderate COVID-19 disease who are unable to self-isolate at home due to crowded quarters or inability to self-care. This effort influenced NYC Council legislation mandating housing for homeless persons with COVID-19.

TAG produced a statement defending the World Health Organization from funding cuts proposed by the U.S. president.

Annette Gaudino co-led efforts to secure the release of incarcerated persons from New York State jails and prisons to protect them from ongoing unacceptable exposure to SARS-CoV-2 and later worked to secure access to COVID-19 vaccines for this population.

Bryn presented a poster on the right to science and access to COVID-19 technologies at the International AIDS Society COVID-19 Conference.

Lizzy Lovinger delivered TAG’s testimony at the October 22 meeting of the FDA’s Vaccine and Related Biologic Products Advisory Committee meeting to support FDA’s maintenance of high standards for oversight and regulatory review of potential vaccines for COVID-19 in the face of political interference.

Annette served as the public health lead in coalition with legal advocates, contributing her expertise from the initial drafting through 11th hour amendment negotiations, persuading the NYS legislature to pass and Governor Cuomo to sign into law the first and only contact tracing confidentiality law, barring law enforcement and immigration authorities from accessing identifying information collected in the course of the COVID-19 response.
## Balance Sheet

### Assets

<table>
<thead>
<tr>
<th></th>
<th>2020</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents</td>
<td>$1,571,364</td>
<td>$1,610,906</td>
</tr>
<tr>
<td>Unconditional Promises to Give</td>
<td>2,465,371</td>
<td>496,981</td>
</tr>
<tr>
<td>Accounts receivable</td>
<td>1,252</td>
<td>7,583</td>
</tr>
<tr>
<td>Prepaid expenses and other current assets</td>
<td>50,247</td>
<td>37,208</td>
</tr>
<tr>
<td>Donated artwork</td>
<td>470,239</td>
<td>492,739</td>
</tr>
<tr>
<td>Security deposit</td>
<td>72,463</td>
<td>72,463</td>
</tr>
<tr>
<td>Property and equipment - net</td>
<td>18,477</td>
<td>18,580</td>
</tr>
<tr>
<td><strong>Total Assets</strong></td>
<td><strong>$4,649,413</strong></td>
<td><strong>$2,736,460</strong></td>
</tr>
</tbody>
</table>

### Liabilities and Net Assets

#### Liabilities

<table>
<thead>
<tr>
<th></th>
<th>2020</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accounts payable and accrued expenses</td>
<td>$48,767</td>
<td>$38,603</td>
</tr>
<tr>
<td>Loan Payable</td>
<td>214,717</td>
<td></td>
</tr>
<tr>
<td>Deferred rent</td>
<td>18,613</td>
<td>33,362</td>
</tr>
<tr>
<td><strong>Total Liabilities</strong></td>
<td><strong>282,097</strong></td>
<td><strong>71,965</strong></td>
</tr>
</tbody>
</table>

#### Net Assets

<table>
<thead>
<tr>
<th></th>
<th>2020</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Without donor restrictions</td>
<td>1,402,831</td>
<td>1,537,543</td>
</tr>
<tr>
<td>With donor restrictions</td>
<td>2,964,485</td>
<td>1,126,952</td>
</tr>
<tr>
<td><strong>Total Net Assets</strong></td>
<td><strong>4,367,316</strong></td>
<td><strong>2,664,495</strong></td>
</tr>
</tbody>
</table>

### Total Liabilities and Net Assets

<table>
<thead>
<tr>
<th></th>
<th>2020</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Liabilities and Net Assets</strong></td>
<td><strong>$4,649,413</strong></td>
<td><strong>$2,736,460</strong></td>
</tr>
</tbody>
</table>

## Statement of Cash Flows

### Cash Flows from Operating Activities

<table>
<thead>
<tr>
<th></th>
<th>2020</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Increase (decrease) in net assets</td>
<td>$1,702,821</td>
<td>($590,354)</td>
</tr>
<tr>
<td>Adjustments to reconcile increase (decrease) in net assets to net cash used by operating activities:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Depreciation</td>
<td>9,776</td>
<td>9,547</td>
</tr>
<tr>
<td>(Increase) decrease in:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unconditional promises to give</td>
<td>(1,968,390)</td>
<td>719,890</td>
</tr>
<tr>
<td>Accounts receivable</td>
<td>6,331</td>
<td>(6,444)</td>
</tr>
<tr>
<td>Prepaid expenses and other assets</td>
<td>(13,039)</td>
<td>(5,614)</td>
</tr>
<tr>
<td>Donated artwork</td>
<td>22,500</td>
<td>(53,000)</td>
</tr>
<tr>
<td>Increase (decrease) in:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accounts payable and accrued expenses</td>
<td>10,164</td>
<td>13,207</td>
</tr>
<tr>
<td>Deferred rent</td>
<td>(14,749)</td>
<td>(9,158)</td>
</tr>
<tr>
<td><strong>Net Cash Used by Operating Activities</strong></td>
<td>(244,586)</td>
<td>78,074</td>
</tr>
</tbody>
</table>

### Cash Flows from Investing Activities

<table>
<thead>
<tr>
<th></th>
<th>2020</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acquisition of property and equipment</td>
<td>(9,673)</td>
<td>(1,399)</td>
</tr>
<tr>
<td><strong>Net Cash Used by Investing Activities</strong></td>
<td>(9,673)</td>
<td>(1,399)</td>
</tr>
</tbody>
</table>

### Cash Flows from Financing Activities

<table>
<thead>
<tr>
<th></th>
<th>2020</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proceeds from loan payable</td>
<td>214,717</td>
<td>-</td>
</tr>
<tr>
<td>Net decrease in cash and cash equivalents</td>
<td>(39,542)</td>
<td>76,675</td>
</tr>
<tr>
<td>Cash and cash equivalents, beginning of year</td>
<td>1,610,906</td>
<td>1,534,231</td>
</tr>
<tr>
<td><strong>Cash and Cash Equivalents, End of Year</strong></td>
<td><strong>$1,571,364</strong></td>
<td><strong>$1,610,906</strong></td>
</tr>
</tbody>
</table>
## Statement of Activities

### Revenue and Other Support

<table>
<thead>
<tr>
<th>Description</th>
<th>Without Donor Restrictions</th>
<th>With Donor Restrictions</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contributions</td>
<td>$511,667</td>
<td>$3,979,681</td>
<td>$4,491,348</td>
</tr>
<tr>
<td>Fundraising benefit events</td>
<td>170,555</td>
<td>-</td>
<td>170,555</td>
</tr>
<tr>
<td>Less: Direct benefit expenses</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Donated artwork, goods and services</td>
<td>336</td>
<td>-</td>
<td>336</td>
</tr>
<tr>
<td>Art sales, net of cost of goods sold</td>
<td>1,700</td>
<td>-</td>
<td>1,700</td>
</tr>
<tr>
<td>Other income</td>
<td>25,978</td>
<td>-</td>
<td>25,978</td>
</tr>
<tr>
<td>Interest income</td>
<td>737</td>
<td>-</td>
<td>737</td>
</tr>
<tr>
<td>Net assets released from restrictions</td>
<td>2,142,148</td>
<td>(2,142,148)</td>
<td>-</td>
</tr>
</tbody>
</table>

|                                                | Without Donor Restrictions | With Donor Restrictions | Total       |
|                                                | 2,853,121                 | 1,837,533               | 4,690,654   |

### Expenses

#### Program Services

<table>
<thead>
<tr>
<th>Program</th>
<th>Without Donor Restrictions</th>
<th>With Donor Restrictions</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV Program</td>
<td>964,172</td>
<td>-</td>
<td>964,172</td>
</tr>
<tr>
<td>Hepatitis C Virus Program</td>
<td>234,426</td>
<td>-</td>
<td>234,426</td>
</tr>
<tr>
<td>Tuberculosis Program</td>
<td>1,277,362</td>
<td>-</td>
<td>1,277,362</td>
</tr>
</tbody>
</table>

| Total Program Services           |                            |                         | 2,475,960   |

#### Supporting Services

<table>
<thead>
<tr>
<th>Service</th>
<th>Without Donor Restrictions</th>
<th>With Donor Restrictions</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Management and general</td>
<td>360,015</td>
<td>-</td>
<td>360,015</td>
</tr>
<tr>
<td>Fundraising</td>
<td>151,858</td>
<td>-</td>
<td>151,858</td>
</tr>
</tbody>
</table>

| Total Expenses                   |                            |                         | 2,987,833   |

### Increase (decrease) in net assets

<table>
<thead>
<tr>
<th>Without Donor Restrictions</th>
<th>With Donor Restrictions</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>(134,712)</td>
<td>1,837,533</td>
<td>1,702,821</td>
</tr>
</tbody>
</table>

### Net assets, beginning of year

<table>
<thead>
<tr>
<th>Without Donor Restrictions</th>
<th>With Donor Restrictions</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>1,537,543</td>
<td>1,126,952</td>
<td>2,664,495</td>
</tr>
</tbody>
</table>

### Net Assets, End of Year

<table>
<thead>
<tr>
<th>Without Donor Restrictions</th>
<th>With Donor Restrictions</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>$1,402,831</td>
<td>$2,964,485</td>
<td>$4,367,316</td>
</tr>
</tbody>
</table>

## Summary of 2020 Functional Expenses

- **Program Services**: 83%
- **Management & Administration**: 12%
- **Fundraising**: 5%
$100,000 or more
The Aurum Institute
Bill and Melinda Gates Foundation
Hopewell Fund
Fred Hutchinson Cancer Research Center
Stop TB Partnership hosted by UNOPS
University of Nebraska Medical Center
ViiV Healthcare

$50,000 to $99,999
Broadway Cares / Equity Fights AIDS
Merck & Co.
Veterans Affairs Medical Center of Washington, DC

$25,000 to $49,999
The Debs Foundation: Richard A. and Barbara Knowles Debs; Nick Debs
David Gold
Housing Works
M·A·C VIVA GLAM Fund
Open Society Foundations

$10,000 to $24,999
The Calamus Foundation
Joseph Evall and Richard M. Lynn
Annie Bennett Glenn Fund of The Winston Salem Foundation
Robert W. Lennon and Mark Gilrain
Médecins du Monde
National TB Controllers Association

$5,000 to $9,999
amfAR, The Foundation for AIDS Research
Sam Avrett and David Barr
Michael Becker and Tee Scatuorchio
Celeste B. Cooper
Federation of Protestant Welfare Agencies
David France
Kevin and Neil Goetz
Hauser & Wirth
Marta Heflin Foundation
Ambassador James C. Hormel and Michael P.N. Hormel
Erica Lessem
Robert Monteleone
Laura A. Morrison
Roche
Jordan Roth and Richie Jackson
William Shea and Frank R. Selvaggi
Barry C. Skovgaard and Marc Wolinsky
John Voelcker
Weil, Gotshal & Manges LLP

$2,500 to $4,999
Columbia University
John F. Duane and Mary E. Northridge
The Gendal Family Foundation
Dr. Michael F. Giordano
Global Health Strategies
Judith Harrington
Mark Harrington
Megan Harrington and Jonathan Creighton
Robert C. Henry
Barbara F. Hughes
Fannie and Stephen Kahn Charitable Foundation
Winston B. Layne
Dr. J. Michael McCune III and Dr. Karen Kaye Smith-McCune
Screen Engine / ASI
Mark M. Sexton and W. Kirk Wallace
The Estate of Samuel J. Silling
Audrey Sokoloff and Tim Hosking
Mrinal Vikram and Kevin Finnegan
The Andrew David Zacks Foundation

$1,000 to $2,499
AbbVie
Jim Aquino
Alejandro and Ivy Kwan Arce
Katherine C. Ash and Thomas M. Ash III
Jack M. Battaglia
Beth Israel Deaconess Medical Center I4C
CAB
Bob Bronzo
Karen Bronzo and Jefferson Rabb
Marisa Cardinale
Susan Chun
Marc E. Elowitz
Jonathan Fine
Catherine Garzio and Martin Mattes
Judy and Steven Gluckstern
Christina and Kenneth Hecht
Brian Hodge
IAVI / International AIDS Vaccine Initiative
Jameel Jiwani
Noel E.D. Kimon and Michael D. Paley
Latino Commission on AIDS
Michael K. Longacre
Jeff Meleski and Steve Markov
Jeff Mendoza and Dr. Chuck Sklar
National Coalition of STD Directors
Donesh Olyaie
Otsuka Novel Products GmbH
Eddie Pelto
Daniel Ptacek
Walter Rienman
Paul Sack
Dr. Bruce Schackman and Edward K. Sikov
Andrew C. Schirmeister III
Evan Schwartz and Robert Fitterman
H.A. "Hal" Sedgwick
Francesco Sedita and Doug Yacka
The Sigal Family Foundation: David Sigal and NY State Senator Brad Hoylman
Peter Staley
Henry Thaggert
Emily Tillman
Rachel B. Tiven and Seth M. Mamin
Dorn Vecchie-Campbell
Margaret Rose Vendryes
Paul Forrest Williams, Jr.
Wistar Institute BEAT-HIV
Tim Wuliger
Max von Zuben

$500 to $999
Acadiana Cares
Moisés Agosto
Richard Aguilar
ATAC / AIDS Treatment Activists Coalition
AVAC / AIDS Vaccine Advocacy Coalition
Ian and Luann Bailey / Vivid Coffee
Margot and Robert J. Bazell
Michael Beltran and Tim Ford
Frank Bua and Scott Carroll
Steven J. and Denise Chickery
Joe Ciancaglini
Benson Cohen
Corey Family Trust: Lawrence Corey, MD
Robert N. Croonquist
Scott Dainton
Arianne Z. Dar / New Ground Fund of Marin Community Foundation
Hon. Thomas K. Duane

2020 TAG CONTRIBUTORS

10 • 2020 TAG ANNUAL REPORT
We would also like to thank those who gave generously to TAG as part of campaigns hosted by Act Blue Charities, PayPal Charitable Giving, and Network for Good for Facebook fundraising campaigns. TAG received funds by participation in the Amazon Smile program, and also received generous Employee Matching Funds from several business giving platforms. TAG would like to thank artist Keith Mayerson and the Red Hot Organization for generous in-kind donation of goods to support the 2020 Research in Action Awards event that benefitted TAG.
About TAG

Treatment Action Group (TAG) is an independent, activist, and community-based research and policy think tank committed to racial, gender, and LGBTQ+ equity; social justice; and liberation, fighting to end HIV, tuberculosis (TB), and hepatitis C virus (HCV).

TAG catalyzes open collective action by affected communities, scientists, and policymakers to ensure that all people living with or impacted by HIV, TB, or HCV — especially communities of color and other marginalized communities experiencing inequities — receive life-saving prevention, diagnosis, treatment, care, and information.

We are science-based activists working to expand and accelerate vital research and effective community engagement with research and policy institutions for an end to the HIV, TB, and HCV pandemics.

Support TAG

Over the past three decades, TAG has been central to the fight against HIV, HCV, and TB. In 2020, we continued our vital core work to end HIV, HCV, and TB while also applying our expertise to the COVID-19 pandemic. A robust response based on science and driven by community priorities is more crucial than ever.

Make a gift to TAG and help us advocate for the needs of all people affected by HIV, HCV, TB, and COVID-19.


Does your organization have a matching gifts program? Don’t miss your chance to make a gift that keeps on giving. Complete and send us your company’s matching gift form to double your contribution’s impact!

TAG Limited Art Editions

Each year, at its Research in Action Awards, TAG presents a new, limited edition work of art. This year, our edition was Homage to America’s Doctor, Anthony S. Fauci by Keith Mayerson. The package also included other now sold-out elements, and was supported by the generosity of Red Hot and the Marta Heflin Foundation. Many TAG art editions, including a few of artist prints of our 2020 edition, are available for sale to the public. All proceeds benefit TAG’s work. If you’re interested in purchasing an edition or learning more, detailed information can be found at https://www.treatmentactiongroup.org/support-us/limited-art-editions/.

2021 BOARD OF DIRECTORS

PRESIDENT: Robert W. Lennon
SECRETARY: Mrinal Vikram
TREASURER: Laura Morrison
Jim Aquino
Nick Debs
Joy Episalla
Kevin Goetz
Roy Gulick, M.D.
Jameel Jiwani
Richard Lynn, Ph.D., M.P.H.
Robert Monteleone
Eddie Pelto
David Sigal

BOARD PRESIDENT EMERITUS:
Barbara Hughes

TAG Board and staff thank Barbara Hughes for her decades of selfless service and wise leadership. We love you, Barbara.

2021 STAFF

EXECUTIVE DIRECTOR:
Mark Harrington
DEPUTY EXECUTIVE DIRECTOR:
Erica Lessem
TB PROJECT OFFICER:
David Branigan
HCV COMMUNITY ENGAGEMENT OFFICER:
Joelle Dountio Ofimbouedem
ANEACOORDINATOR:
Edric Figueroa
TB PROJECT CO-DIRECTOR:
Mike Frick
DIRECTOR OF POLICY STRATEGY:
Annette Gaudino
HCV PROJECT DIRECTOR:
Bryn Gay
FINANCE MANAGER:
Christopher George
DIRECTOR OF FINANCE AND OPERATIONS:
Sabrina Guerrero-Morris
BASIC SCIENCE, VACCINES, AND CURE PROJECT DIRECTOR:
Richard Jefferys
HIV COMMUNITY ENGAGEMENT OFFICER:
Abraham Johnson
HIV PROJECT DIRECTOR:
Jeremiah Johnson
GRANT OFFICER:
Jason Kirk
 SENIOR GOVERNMENT RELATIONS AND POLICY OFFICER:
Elizabeth Lovinger
U.S. AND GLOBAL HEALTH POLICY DIRECTOR:
Suraj Madoori
ADMINISTRATOR:
Joseph McConnell
TB PROJECT CO-DIRECTOR:
Lindsay McKenna
COMMUNICATIONS MANAGER:
Dorrit Walsh

Charity Navigator
Four Star Charity